CORE--CLINICAL

随着神经退行性痴呆研究的戏剧性扩展和方法的复杂性，对临床核心的要求变得更加复杂，这些样本包括明确定义的AD患者和相关痴呆、轻度认知障碍(MCI)、路易体谱病和年龄匹配的对照组。适合于一种类型的研究(如临床治疗结果试验)的受试者样本通常不适合于其他类型的研究(例如，病例对照流行病学研究或遗传连锁分析)。此外，还需要其他类型的样本来培训临床医生处理在痴呆症过程中表现出的多种临床问题。为了满足这些多重需求， 临床核心已经开发并将继续提供AD患者、非AD痴呆患者、MCI和正常健康对照受试者的多个样本，适合支持广泛的神经退行性痴呆症研究和临床培训的受试者招募需求。临床核心将继续包括可能的AD和非痴呆的老年对照，以最大限度地适合参与临床研究。为了遵循NIA的指导，将重点放在AD的早期阶段和从正常衰老的过渡，我们将专注于增加早期AD、MCI和认知正常的老年对照组的受试者样本。此外，患有非AD神经退行性痴呆障碍和路易身体谱系疾病的受试者将被招募，并在临床核心中进行跟踪。临床核心人员 支持并与适合于流行病学研究的老年痴呆症和正常对照受试者的基于人群的队列进行互动，这为死后脑组织的加入提供了额外的来源。临床核心人员将继续收集这些受试者的脑脊液(CSF)、血浆和血清，并通过与多个ADC的合作努力，继续扩大大型UW ADRC脑脊液数据库，以支持搜索用于诊断和监测痴呆疾病疾病进展的生物标记物。通过所有这些受试者群体、受试者、生物流体样本和数据 为满足ADRC调查人员、更广泛的华盛顿大学研究界的其他适当调查人员以及其他机构的调查人员的研究需要而提供。

With the dramatic expansion and increased methodological sophistication in neurodegenerative dementia research, demands on the Clinical Core for clearly defined samples of persons with AD and related dementias, mild cognitive impairment (MCI), Lewy body spectrum disease, and age-matched controls have become more complex. A sample of subjects appropriate for one type of investigation (such as a clinical treatment outcome trial) is often not appropriate for other types of studies (for example, a case-control epidemiologic study or genetic linkage analysis). Still other types of samples are needed for training clinicians to manage the multiple clinical problems expressed during the course of dementia. To meet these multiple demands, the Clinical Core has developed and will continue to provide multiple samples of AD patients, non-AD dementia patients, MCI, and normal healthy control subjects suitable for supporting the subject recruitment needs of a broad range of research and clinical training in neurodegenerative dementias. The Clinical Core will continue to include probable AD and nondemented older controls selected for maximum appropriateness for participation in clinical studies. To comply with NIA guidance to focus on earlier stages of AD and the transition from normal aging, we will focus on increasing subject samples with early AD, MCI, and cognitively normal older controls. In addition, subjects with non-AD neurodegenerative dementing disorders and Lewy body spectrum disease will be recruited and followed in the Clinical Core. Clinical Core personnel support and interact with population-based cohorts of late life dementia and normal control subjects appropriate for epidemiologic studies and which provide additional sources for accession of postmortem brain tissue. Clinical Core personnel will continue to collect cerebrospinal fluid (CSF), plasma and serum on these subject samples and through collaborative efforts with multiple ADCs, continue to expand the large UW ADRC CSF bank to support the search for biomarkers for diagnosis and monitoring disease progression of dementing disorders. Through all these subject populations, subjects, biological fluid samples, and data are provided to meet the research needs of ADRC investigators, other appropriate investigators in the broader University of Washington research community, and investigators at other institutions.